Fibre supplementation increased the risk for recurrent adenomas, and calcium supplementation did not prevent recurrence
Year: 2001
Type: article
Abstract: (2000) Lancet 356, 1300. Bonithon–Kopp C, Kronborg O, Giacosa A, et al . , for the European Cancer Prevention Organisation Study Group. . Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial. . Oct 14; . : . –6 . [OpenUrl][1][CrossRef][2][PubMed][3][Web of Science][4] QUESTION: In patients with colorectal adenomas, does supplementation with ispaghula husk or calcium prevent adenoma recurrence? Randomised (allocation concealed*), blinded (patients, clinical staff, and investigators),* placebo controlled trial with 3 years follow up. 21 centres in 10 countries (Belgium, Denmark, France, Germany, Ireland, Israel, Italy, Portugal, Spain, and the UK). 665 patients who were 35–75 years of age, had a complete index colonoscopy showing ≥2 adenomas or 1 adenoma of >5 mm in diameter, and did not have a debilitating or life threatening disease. Exclusion criteria were history of large bowel disease, contraindications to calcium or fibre, or inability or unwillingness to stop current fibre or calcium supplementation. 552 patients (83%, mean age 59 y, 64% men) … [1]: {openurl}?query=rft.jtitle%253DLancet%26rft.stitle%253DLancet%26rft.aulast%253DBonithon-Kopp%26rft.auinit1%253DC.%26rft.volume%253D356%26rft.issue%253D9238%26rft.spage%253D1300%26rft.epage%253D1306%26rft.atitle%253DCalcium%2Band%2Bfibre%2Bsupplementation%2Bin%2Bprevention%2Bof%2Bcolorectal%2Badenoma%2Brecurrence%253A%2Ba%2Brandomised%2Bintervention%2Btrial.%2BEuropean%2BCancer%2BPrevention%2BOrganisation%2BStudy%2BGroup.%26rft_id%253Dinfo%253Adoi%252F10.1016%252FS0140-6736%252800%252902813-0%26rft_id%253Dinfo%253Apmid%252F11073017%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx [2]: /lookup/external-ref?access_num=10.1016/S0140-6736(00)02813-0&link_type=DOI [3]: /lookup/external-ref?access_num=11073017&link_type=MED&atom=%2Febmed%2F6%2F3%2F90.atom [4]: /lookup/external-ref?access_num=000089858300009&link_type=ISI
Source: BMJ Evidence-Based Medicine
DOI: 10.1136/ebm.6.3.90
Author: R. H Fletcher
Institution: Harvard University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2152011976